查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1577492

照护现场感染疾病诊断的全球市场

Point-of-Care Infectious Disease Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 287 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球照护现场感染疾病诊断市场预计将达到 53 亿美元

全球照护现场感染疾病诊断市场预计 2023 年为 26 亿美元，预计到 2030 年将达到 53 亿美元，2023-2030 年分析期间复合年增长率为 10.8%。侧流免疫检测是本报告分析的细分市场之一，预计复合年增长率为 11.6%，到分析期结束时将达到 27 亿美元。分析期内，流通式测试领域的复合年增长率预计为10.6%。

美国市场预估为7.113亿美元，中国预期复合年增长率为14.8%

到 2023 年，美国照护现场感染疾病诊断市场预计将达到 7.113 亿美元。中国作为世界第二大经济体，预计2030年市场规模将达12亿美元，2023-2030年分析期间复合年增长率为14.8%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 8.0% 和 9.3%。在欧洲，德国预计复合年增长率为 8.5%。

全球照护现场感染疾病诊断市场—主要趋势与驱动因素总结

为什么照护现场感染疾病诊断将改变医疗保健服务和病患治疗结果。

照护现场(POC)感染疾病诊断透过在患者照护点或附近对感染疾病进行快速、准确和分散式检查，正在彻底改变医疗保健。这些诊断包括各种测试，例如横向流动化验、快速抗原测试、分子诊断测定和免疫测量，并且可以在传统实验室之外进行，使医疗保健专业人员能够及时获得重要资讯。与需要密集实验室、专业设备和长时间测试的传统诊断方法不同，POC 诊断方法可以在几分钟到几小时内提供结果，从而可以立即诊断并开始治疗。这种快速检测能力对于爱滋病毒、结核病、流感和性行为感染感染（STI）等感染疾病的管理尤其重要，早期发现和及时治疗对于减少疾病传播并改善患者治疗效果极为重要。

POC感染疾病诊断方法越来越多地被采用，是因为它们能够改善检测的机会，特别是在偏远、资源有限和服务不足的地区。这些诊断不需要复杂的测试基础设施，允许在农村诊所、社区健康中心甚至患者家用中进行测试。这种可近性对于应对全球健康挑战至关重要，特别是在医疗保健资源有限和感染疾病负担较高的低收入和中等收入国家。此外，POC 诊断的便利性和易用性提高了患者的依从性并减少了后续观察的需要，从而支持更有效率的医疗服务并减轻医疗保健系统的负担。随着快速、分散检测的需求不断增长，POC感染疾病诊断对于全球健康将变得越来越重要，在更好的疾病管理、更快的疫情应对以及更有效的感染疾病控制方面开始发挥作用。

哪些技术进步正在推动照护现场感染疾病诊断的发展和广泛使用？

技术进步显着提高了照护现场感染疾病诊断的准确性、速度和多功能性，使其更加有效和广泛适用。该领域最具创新性的创新之一是分子 POC 诊断的开发，该诊断使用聚合酵素链锁反应(PCR) 和等温扩增等技术在基因层面上检测病原体。分子诊断方法灵敏且特异，甚至可以检测患者检体中低水平的病原体。分子诊断平台的小型化和实验室晶片技术的整合使得在护理点进行复杂的分子测试成为可能，其结果与中心实验室获得的结果相当。这些进步扩大了分子 POC 诊断的用途，以检测多种病原体，包括细菌、病毒和真菌，并使得多重检测能够从单一样本同时识别多种感染疾病。

另一项重要的技术进步是快速抗原和抗体测试的发展，它可以提供即时结果来检测活动性感染疾病或病原体暴露史。侧向层析检测（LFA）是一种常见的快速抗原检测，广泛用于检测COVID-19、流感、疟疾和HIV等感染疾病。这些测试易于使用、便携，并在几分钟内提供结果，非常适合在临床和非临床环境中使用。侧流技术的最新创新，例如增强的讯号检测和奈米颗粒标籤的使用，提高了这些测试的灵敏度和可靠性，支持它们在疾病监测和社区筛检计画中的广泛采用。此外，采用基于智慧型手机的读出系统的下一代侧流分析的开发正在实现数位分析和即时资料共用，从而增加了 POC 诊断与数位健康平台的整合。

数位科技与人工智慧（AI）的融合进一步加速了照护现场感染疾病诊断的发展。数位 POC 诊断具有连接功能，可将测试结果发送到电子健康记录(EHR)、云端基础的平台和行动应用程序，从而实现远端监控和远端健康咨询。人工智慧和机器学习演算法的使用增强了对测试结果的解释，减少了人为错误的可能性，并为临床医生提供了可行的见解。使用人工智慧的 POC 诊断也用于开发疾病发生的预测模型并优化现场诊断工作流程。数位科技与人工智慧的结合可以实现更有效率的资料收集、分析和报告，使POC诊断成为公共卫生监测和流行病学研究的强大工具。随着技术的进步，POC感染疾病的诊断预计将变得更加准确、更容易获得，并整合到更广泛的医疗保健系统中，从而实现更有效的疾病管理和控制。

市场动态与监理标准如何形塑照护现场感染疾病诊断市场？

照护现场感染疾病诊断市场是由影响产品开拓、采用和商业化的市场动态、监管标准和医疗保健趋势之间的复杂相互作用形成的。市场驱动因素之一是已开发国家和新兴国家感染疾病的日益流行，这推动了对快速且易于使用的检测解决方案的需求。爱滋病毒、结核病、肝炎和疟疾等感染疾病继续对全球健康构成重大挑战，特别是在诊断基础设施有限的低收入和中等收入国家。最近的 COVID-19 大流行进一步凸显了快速、广泛检测的必要性，并凸显了 POC 诊断在疫情应对和公共卫生管理中的关键作用。随着世界各地的医疗保健系统努力改善感染疾病的检测和控制，对能够快速有效地提供可靠结果的 POC 诊断的需求预计将会增加。

监管标准和合规要求在塑造照护现场感染疾病诊断市场方面也发挥着重要作用。监管机构，例如美国食品药物管理局(FDA)、欧洲药品管理局 (EMA) 和其他地区机构，对诊断测试的开发、核准和商业化实施严格的规定，以确保其安全性、有效性和可靠性。遵守这些法规对于製造商进入市场并维持医疗保健提供者和患者的信任至关重要。监管环境正在不断发展，以适应 POC 诊断的快速发展和部署，特别是为了应对突发公共卫生事件。例如，FDA 的紧急使用核准(EUA) 流程在 COVID-19 大流行期间得到了广泛使用，以促进 SARS-CoV-2 快速检测的快速核准，并促进在医疗保健和社区环境中的快速分发和分发。其他地区正在考虑类似的监管途径，以支持新兴感染疾病的 POC 诊断的开发。

製造商之间的竞争、技术创新和医疗保健报销政策等市场动态也正在影响照护现场感染疾病诊断市场。竞争格局的特点是成熟的诊断製造商和创新新兴企业，每个製造商都在努力开发新颖的 POC 测试解决方案，以提供卓越的性能、易用性和经济性。每家公司都透过产品创新、策略伙伴关係以及提供全面诊断解决方案（包括仪器、试剂和数位健康整合）的能力来使自己脱颖而出。价格压力很大，尤其是在成本敏感的市场，推动了对低成本 POC 测试的需求，这些测试可以在不影响品质的情况下提供高性能。此外，医疗保健报销政策和付款人的承保范围决定也会影响 POC 测试产品的采用，因为 POC 测试产品的可用性和可负担性通常由报销决定。报销环境因地区而异，并受到测试的临床效用、替代诊断选项的可用性以及整体医疗保健预算等因素的影响。对于在未满足的关键字市场中经营的公司来说，利用这些市场动态和监管标准至关重要，因为他们寻求扩大其影响力并满足全球患者和医疗保健提供者未满足的诊断需求。

推动照护现场感染疾病诊断市场扩张的关键成长要素是什么？

全球照护现场感染疾病诊断市场的成长是由几个关键因素推动的，包括感染疾病病率的增加、对快速和分散检测解决方案的需求不断增长以及诊断技术的进步。关键的成长要素之一是全球感染疾病率的上升，对支持早期检测和及时治疗决策的诊断工具产生了巨大需求。爱滋病毒、结核病、肝炎和性行为感染感染（STI）等感染疾病仍然是重大的公共卫生挑战，特别是在低收入和中等收入国家。 POC 诊断透过在农村诊所、社区健康中心和居家医疗机构等分散环境中实现快速、准确的检测，在应对这些挑战方面发挥着重要作用。 POC 诊断可以在护理点快速提供结果，改善患者接受检测的机会，实现早期诊断并立即开始治疗。

另一个主要的成长要素是人们越来越关注快速且分散的检测解决方案，特别是在 COVID-19 大流行等全球突发卫生事件期间。这场大流行凸显了可扩展且易于使用的诊断解决方案对于限制疾病传播和管理公共卫生的重要性。 POC 诊断不需要复杂的测试基础设施并提供即时结果，已成为对抗 COVID-19 和其他新兴感染疾病的重要工具。随着医疗保健系统寻求建立更具弹性和快速的诊断能力，在大流行期间获得的经验预计将有助于继续采用其他感染疾病的 POC 诊断。对家庭测试和自我测试选项不断增长的需求也促进了市场成长，因为这些测试非常方便，并且支援非传统医疗保健环境中的疾病管理。

诊断技术的进步进一步推动了照护现场感染疾病诊断市场的扩张。分子 POC 平台、数位诊断和连接功能等创新正在推动测试的开发，提供更高的灵敏度、特异性和易用性。分子 POC 平台利用 PCR 和等温扩增等技术，提供高度准确的结果，可检测从细菌、病毒到真菌等多种病原体。借助基于智慧型手机的读取系统和云端连接的数位诊断可实现远端监控并与远端医疗平台集成，支援更全面的疾病管理和监测。可以从单一样本同时检测多种病原体的多重 POC 测试的发展也扩展了 POC 诊断的能力，使其更加通用和高效。

最后，对公共卫生措施的日益关注和新兴市场诊断基础设施的扩大正在促进照护现场感染疾病诊断市场的成长。在亚太地区、非洲和拉丁美洲等感染疾病负担较高且实验室检测机会有限的地区，POC 诊断提供了改善疾病检测和控制的解决方案。各国政府、非营利组织和国际卫生组织正在投资诊断基础设施和以地区为基础的检测项目，以增加获得医疗保健的机会并减轻疾病负担。在这些地区，负担得起的 POC 诊断变得越来越容易获得，支持广泛的检测和改善的医疗保健结果。感染疾病，全球照护现场感染呈上升趋势。进步、应用范围扩大以及对快速和分散测试解决方案的日益重视推动了持续成长。

受访企业范例（共38家）

  • AccuBioTech Co., Ltd.
  • Agilent Technologies, Inc.
  • BioFire Diagnostics LLC
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Cepheid
  • Chembio Diagnostic Systems, Inc.
  • Danaher Corporation
  • EKF Diagnostics Holdings PLC

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP24400

Global Point-of-Care Infectious Disease Diagnostics Market to Reach US$5.3 Billion by 2030

The global market for Point-of-Care Infectious Disease Diagnostics estimated at US$2.6 Billion in the year 2023, is expected to reach US$5.3 Billion by 2030, growing at a CAGR of 10.8% over the analysis period 2023-2030. Lateral Flow Immunoassay Technique, one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Flow-through Test Technique segment is estimated at 10.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$711.3 Million While China is Forecast to Grow at 14.8% CAGR

The Point-of-Care Infectious Disease Diagnostics market in the U.S. is estimated at US$711.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 14.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 9.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Point-of-Care Infectious Disease Diagnostics Market - Key Trends & Drivers Summarized

Why Are Point-of-Care Infectious Disease Diagnostics Transforming Healthcare Delivery and Patient Outcomes?

Point-of-care (POC) infectious disease diagnostics are revolutionizing healthcare by enabling rapid, accurate, and decentralized testing of infectious diseases at or near the site of patient care. These diagnostics include a range of tests, such as lateral flow assays, rapid antigen tests, molecular diagnostic assays, and immunoassays, which can be performed outside traditional laboratory settings, providing healthcare providers with critical information for timely clinical decision-making. Unlike conventional diagnostic methods that require centralized laboratories, specialized equipment, and longer turnaround times, POC diagnostics deliver results within minutes to hours, allowing for immediate diagnosis and initiation of treatment. This rapid testing capability is particularly vital in the management of infectious diseases such as HIV, tuberculosis, influenza, and sexually transmitted infections (STIs), where early detection and prompt treatment are crucial to controlling disease spread and improving patient outcomes.

The growing adoption of POC infectious disease diagnostics is driven by their ability to increase access to testing, particularly in remote, resource-limited, and underserved areas. These diagnostics eliminate the need for complex laboratory infrastructure, making it possible to perform testing in rural clinics, community health centers, and even in patients’ homes. This accessibility is crucial for addressing global health challenges, especially in low- and middle-income countries where healthcare resources are limited and the burden of infectious diseases is high. Moreover, the convenience and ease of use of POC diagnostics enhance patient compliance and reduce the need for follow-up visits, supporting more efficient healthcare delivery and reducing the burden on healthcare systems. As the demand for rapid and decentralized testing continues to grow, POC infectious disease diagnostics are poised to play an increasingly important role in global health, enabling better disease management, faster outbreak response, and more effective control of infectious diseases.

What Technological Advancements Are Driving the Evolution and Adoption of Point-of-Care Infectious Disease Diagnostics?

Technological advancements are significantly enhancing the accuracy, speed, and versatility of point-of-care infectious disease diagnostics, making them more effective and widely applicable. One of the most transformative innovations in this field is the development of molecular POC diagnostics, which utilize techniques such as polymerase chain reaction (PCR) and isothermal amplification to detect pathogens at the genetic level. Molecular diagnostics offer high sensitivity and specificity, enabling the detection of even low levels of pathogens in patient samples. The miniaturization of molecular diagnostic platforms and the integration of lab-on-a-chip technologies are making it possible to perform complex molecular tests at the point of care, providing results that are comparable to those obtained in centralized laboratories. These advancements are expanding the use of molecular POC diagnostics for detecting a wide range of pathogens, including bacteria, viruses, and fungi, and are enabling multiplex testing to identify multiple infections simultaneously from a single sample.

Another significant technological advancement is the development of rapid antigen and antibody tests, which provide immediate results for detecting active infections or prior exposure to pathogens. Lateral flow assays (LFAs), a common type of rapid antigen test, are widely used for detecting infectious diseases such as COVID-19, influenza, malaria, and HIV. These tests are designed to be user-friendly, portable, and capable of delivering results within minutes, making them ideal for use in both clinical and non-clinical settings. Recent innovations in lateral flow technology, such as enhanced signal detection and the use of nanoparticle labels, are improving the sensitivity and reliability of these tests, supporting their broader adoption in disease surveillance and community screening programs. Additionally, the development of next-generation lateral flow assays with smartphone-based readout systems is enabling digital analysis and real-time data sharing, enhancing the integration of POC diagnostics into digital health platforms.

The integration of digital technologies and artificial intelligence (AI) is further driving the evolution of point-of-care infectious disease diagnostics. Digital POC diagnostics are being developed with connectivity features that allow them to transmit test results to electronic health records (EHRs), cloud-based platforms, or mobile apps, enabling remote monitoring and telehealth consultations. The use of AI and machine learning algorithms is enhancing the interpretation of test results, reducing the potential for human error, and providing actionable insights for clinicians. AI-driven POC diagnostics are also being used to develop predictive models for disease outbreaks and to optimize diagnostic workflows in field settings. The combination of digital technologies and AI is enabling more efficient data collection, analysis, and reporting, making POC diagnostics powerful tools for public health monitoring and epidemiological research. As technology continues to advance, POC infectious disease diagnostics are expected to become even more accurate, accessible, and integrated with broader healthcare systems, supporting more effective disease management and control.

How Are Market Dynamics and Regulatory Standards Shaping the Point-of-Care Infectious Disease Diagnostics Market?

The point-of-care infectious disease diagnostics market is shaped by a complex interplay of market dynamics, regulatory standards, and healthcare trends that are influencing product development, adoption, and commercialization. One of the primary market drivers is the increasing prevalence of infectious diseases, both in developed and developing regions, which is creating a growing demand for rapid and accessible testing solutions. Infectious diseases such as HIV, tuberculosis, hepatitis, and malaria continue to pose significant health challenges globally, particularly in low- and middle-income countries where diagnostic infrastructure is limited. The recent COVID-19 pandemic has further underscored the need for rapid and widespread testing, highlighting the critical role of POC diagnostics in outbreak response and public health management. As healthcare systems around the world strive to improve infectious disease detection and control, the demand for POC diagnostics that can deliver reliable results quickly and efficiently is expected to rise.

Regulatory standards and compliance requirements are also playing a crucial role in shaping the point-of-care infectious disease diagnostics market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regional bodies have established stringent guidelines for the development, approval, and commercialization of diagnostic tests to ensure their safety, efficacy, and reliability. Compliance with these regulations is essential for manufacturers to gain market access and maintain the trust of healthcare providers and patients. The regulatory landscape is evolving to accommodate the rapid development and deployment of POC diagnostics, particularly in response to public health emergencies. For example, the FDA’s Emergency Use Authorization (EUA) process, which was widely used during the COVID-19 pandemic, facilitated the expedited approval of rapid tests for SARS-CoV-2, enabling their rapid distribution and use in healthcare and community settings. Similar regulatory pathways are being explored in other regions to support the development of POC diagnostics for emerging infectious diseases.

Market dynamics such as competition among manufacturers, technological innovation, and healthcare reimbursement policies are also influencing the point-of-care infectious disease diagnostics market. The competitive landscape is characterized by the presence of established diagnostic companies and innovative startups, each striving to develop novel POC testing solutions that offer superior performance, ease of use, and affordability. Companies are differentiating themselves through product innovation, strategic partnerships, and the ability to provide comprehensive diagnostic solutions that include devices, reagents, and digital health integrations. Pricing pressures, particularly in cost-sensitive markets, are driving the demand for low-cost POC tests that offer high performance without compromising quality. Additionally, healthcare reimbursement policies and coverage decisions by payers are impacting the adoption of POC diagnostics, as reimbursement often determines the accessibility and affordability of these products. Reimbursement environments vary significantly across regions and are influenced by factors such as the clinical utility of the test, the availability of alternative diagnostic options, and the overall healthcare budget. Navigating these market dynamics and regulatory standards is essential for companies operating in the point-of-care infectious disease diagnostics market as they seek to expand their presence and address the unmet diagnostic needs of patients and healthcare providers worldwide.

What Are the Key Growth Drivers Fueling the Expansion of the Point-of-Care Infectious Disease Diagnostics Market?

The growth in the global point-of-care infectious disease diagnostics market is driven by several key factors, including the increasing prevalence of infectious diseases, the growing demand for rapid and decentralized testing solutions, and advancements in diagnostic technologies. One of the primary growth drivers is the rising incidence of infectious diseases worldwide, which is creating a significant need for diagnostic tools that can provide early detection and support timely treatment decisions. Infectious diseases such as HIV, tuberculosis, hepatitis, and sexually transmitted infections (STIs) continue to be major public health challenges, particularly in low- and middle-income countries. Point-of-care diagnostics are playing a critical role in addressing these challenges by enabling rapid and accurate testing in decentralized settings, such as rural clinics, community health centers, and home care environments. The ability of POC diagnostics to deliver results quickly and at the site of care is enhancing patient access to testing, supporting early diagnosis, and enabling immediate initiation of treatment, which is crucial for improving patient outcomes and reducing disease transmission.

Another significant growth driver is the increasing focus on rapid and decentralized testing solutions, particularly in the context of global health emergencies such as the COVID-19 pandemic. The pandemic has highlighted the importance of scalable and accessible diagnostic solutions for controlling disease spread and managing public health. POC diagnostics, with their ability to provide real-time results without the need for complex laboratory infrastructure, have become essential tools in the fight against COVID-19 and other emerging infectious diseases. The experience gained during the pandemic is expected to drive the continued adoption of POC diagnostics for other infectious diseases, as healthcare systems seek to build more resilient and responsive diagnostic capabilities. The growing demand for at-home and self-testing options is also contributing to market growth, as these tests offer convenience and support disease management in non-traditional healthcare settings.

Advancements in diagnostic technologies are further fueling the expansion of the point-of-care infectious disease diagnostics market. Innovations such as molecular POC platforms, digital diagnostics, and connectivity features are enabling the development of tests that offer higher sensitivity, specificity, and ease of use. Molecular POC platforms, which utilize techniques such as PCR and isothermal amplification, are providing highly accurate results for detecting a wide range of pathogens, from bacteria and viruses to fungi. Digital diagnostics with smartphone-based readout systems and cloud connectivity are enabling remote monitoring and integration with telehealth platforms, supporting more comprehensive disease management and surveillance. The development of multiplex POC tests, which can detect multiple pathogens simultaneously from a single sample, is also expanding the capabilities of POC diagnostics, making them more versatile and efficient.

Lastly, the increasing focus on public health initiatives and the expansion of diagnostic infrastructure in emerging markets are contributing to the growth of the point-of-care infectious disease diagnostics market. In regions such as Asia-Pacific, Africa, and Latin America, where the burden of infectious diseases is high and access to laboratory testing is limited, POC diagnostics are providing a solution for improving disease detection and control. Governments, non-profit organizations, and global health agencies are investing in diagnostic infrastructure and community-based testing programs to enhance access to care and reduce disease burden. The increasing availability of affordable POC diagnostics in these regions is supporting the broader adoption of testing and improving health outcomes. As demand from key sectors such as public health, primary care, and home healthcare continues to rise, and as manufacturers innovate to meet evolving healthcare needs, the global point-of-care infectious disease diagnostics market is expected to witness sustained growth, driven by advancements in technology, expanding applications, and the increasing emphasis on rapid and decentralized testing solutions.

Select Competitors (Total 38 Featured) -

  • AccuBioTech Co., Ltd.
  • Agilent Technologies, Inc.
  • BioFire Diagnostics LLC
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Cepheid
  • Chembio Diagnostic Systems, Inc.
  • Danaher Corporation
  • EKF Diagnostics Holdings PLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Point-of-Care Infectious Disease Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Early Diagnosis and Disease Prevention Drives Growth in Point-of-Care Infectious Disease Diagnostics Market
    • Increasing Adoption of Rapid Diagnostic Tests Expands Addressable Market for Point-of-Care Solutions
    • Case Overview: Growth in Global Infectious Disease Burden Bodes Well for Point-of-Care Diagnostics Market Expansion
    • Focus on Reducing Diagnostic Turnaround Time and Enhancing Patient Outcomes Strengthens Business Case for Market Adoption
    • Case Overview: Growth in Adoption of Point-of-Care Testing in Emergency and Critical Care Settings Expands Market Reach
    • Rising Focus on Infectious Disease Surveillance and Epidemiology Expands Market Opportunities
    • Increasing Use of Point-of-Care Diagnostics in Home Healthcare and Self-Testing Expands Market Scope
    • Case Overview: Growth in Digital Health Platforms and Telemedicine Drives Demand for Point-of-Care Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Point-of-Care Infectious Disease Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Lateral Flow Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Lateral Flow Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Lateral Flow Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Flow-through Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Flow-through Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Flow-through Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Agglutination Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Agglutination Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Agglutination Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Home End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Home End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Home End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Assisted Living Healthcare Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Assisted Living Healthcare Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Assisted Living Healthcare Facilities End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • JAPAN
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • CHINA
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • EUROPE
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • FRANCE
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • GERMANY
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • INDIA
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 125: India Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 128: India Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: India 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
  • AFRICA
    • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION